Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV immunotherapy (VTP-300) combined with low-dose nivolumab (LDN) in virally suppressed patients with CHB on nucleos (t)ide analogues

Evans, Tom; Barnes, Eleanor; Mehta, Reena; Bussey, Louise; Anderson, Katie; Vardeu, Antonella; Brown, Anthony; Lim, Young-Suk; Chuang, Wan‐Long; Chen, Chi-Yi; Tak, Won Young; Lo, Gin‐Ho

doi:10.1016/s0168-8278(23)03313-5

Search citation statements

Order By: Relevance

Paper Sections

Select...

Immune Targets1

Therapeutic Vaccination1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In VTP-300 monotherapy, 3 out of 18 patients had significant qHBsAg declined by 0.7, 0.7, and 1.4 log, respectively, although these responding patients all had baseline qHBsAg <50 IU/mL. In patients receiving VTP-300 with a single loading dose of nivolumab, the mean qHBsAg reduction was 0.76 log at 3 months 10 . Therapeutic vaccines may have potential roles in combination strategies.…”

Section: Immune Targetsmentioning

confidence: 96%

See 1 more Smart Citation

Therapeutic advances in HBV cure

Hui,

Mak,

Seto

et al. 2024

Clinical Liver Disease

View full text Add to dashboard Cite

Section: Immune Targetsmentioning

confidence: 96%

“…In patients receiving VTP-300 with a single loading dose of nivolumab, the mean qHBsAg reduction was 0.76 log at 3 months. [10] Therapeutic vaccines may have potential roles in combination strategies.…”

Section: Therapeutic Vaccinationmentioning

confidence: 99%